Mitsubishi UFJ Asset Management’s ImmunityBio IBRX Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-46,433	Closed	-$260K	–	1172
2022 Q1	$260K	Buy	46,433 +2,387	+5%	+$14.6K	﹤0.01%	1020
2021 Q4	$332K	Buy	44,046 +24,367	+124%	+$183K	﹤0.01%	994
2021 Q3	$192K	Hold	19,679	–	–	﹤0.01%	1073
2021 Q2	$281K	Sell	19,679 -24,265	-55%	-$401K	﹤0.01%	1049
2021 Q1	$1.04M	Buy	43,944 +14,843	+51%	+$385K	0.01%	790
2020 Q4	$388K	Buy	+29,101	New	+$280K	﹤0.01%	861

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Mitsubishi UFJ Asset Management's IBRX Position: Q2 2022 in Review

Mitsubishi UFJ Asset Management sold out of ImmunityBio (IBRX) in Q2 2022, closing a stake of 46,433 shares — an estimated $260K sold.

Mitsubishi UFJ Asset Management first reported a position in IBRX in Q4 2020 and held it in 6 quarters. The position peaked at $1.04M in Q1 2021. 131 funds tracked by Wall St. Rank hold IBRX as of Q2 2022.

Mitsubishi UFJ Asset Management reported no remaining ImmunityBio position as of Q2 2022 after selling out during the quarter.
Mitsubishi UFJ Asset Management sold 46,433 ImmunityBio shares in Q2 2022, an estimated $260K.
Mitsubishi UFJ Asset Management first reported a position in ImmunityBio in Q4 2020 and held it in 6 quarters.
Mitsubishi UFJ Asset Management's ImmunityBio position peaked at $1.04M in Q1 2021.
131 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2022.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.